2018
Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation
Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. Annals Of Hematology 2018, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.Peer-Reviewed Original ResearchConceptsUnrelated donor allogeneic stem cell transplantationDonor allogeneic stem cell transplantationAllogeneic stem cell transplantationSingle-institution pilot studyHost disease (GVHD) prophylaxisShort-course methotrexateStem cell transplantationDisease prophylaxisCell transplantationPilot studyProphylaxisTacrolimusSirolimusTransplantationMethotrexateGraft
2015
The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD
Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.Peer-Reviewed Original ResearchConceptsGastrointestinal acute GVHDAcute GVHDGrade IIIAllogeneic stem cell transplantCombination of basiliximabSevere GI GvHDSevere grade IIISteroid-refractory diseaseLong-term survivorsStem cell transplantOverall response rateCurrent retrospective studyChronic GVHDGI GVHDSalvage therapySteroid therapyPrimary diseaseCell transplantMedian timeSignificant morbidityPoor outcomeRetrospective studyGVHDMost deathsNew agentsOutcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts
Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD. Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts. Journal Of Clinical Investigation 2015, 125: 2677-2689. PMID: 26053664, PMCID: PMC4563691, DOI: 10.1172/jci81229.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdrenal Cortex HormonesAdultAnimalsChronic DiseaseDisease-Free SurvivalFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHumansKaplan-Meier EstimateLeukemiaLymphocyte DepletionMaleMiceMiddle AgedMyelodysplastic SyndromesTissue DonorsT-Lymphocyte SubsetsTransplantation ConditioningTransplantation, HomologousYoung AdultConceptsHematopoietic stem cell transplantationStem cell graftsChronic GVHDT cellsCell graftsT-cell-depleted stem cell graftsPeripheral blood stem cell graftsAllogeneic hematopoietic stem cell transplantationBlood stem cell graftsFunctional T-cell memoryT-cell-replete graftsPathogen-specific T cellsSingle-arm clinical trialT-cell recoveryVirus-specific immunityStem cell allograftsTotal body irradiationMemory T cellsStem cell transplantationT cell memoryAcute leukemia patientsHigh-risk leukemiaNaive T cellsAcute GVHDSevere GVHD
2003
Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma
Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplantation 2003, 32: 763-769. PMID: 14520419, DOI: 10.1038/sj.bmt.1704233.Peer-Reviewed Original ResearchConceptsPeripheral blood stem cellsNon-Hodgkin lymphomaNonrelapse mortalityAutologous transplantAllogeneic peripheral blood stem cell transplantationPoor-prognosis non-Hodgkin's lymphomaPeripheral blood stem cell transplantationBlood stem cell transplantationHost disease (GVHD) prophylaxisMini-dose methotrexateLow-grade histologyReduced-intensity conditioningStem cell transplantationBlood stem cellsHigh-grade lymphomaAbnormal organ functionAblative regimensLymphoma effectPrevious transplantAdditional therapyIntravenous busulfanPost transplantPotent graftAllogeneic transplantsOverall survival
2000
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease
Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Annals Of Oncology 2000, 11: 665-672. PMID: 10942053, DOI: 10.1023/a:1008396525292.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsCarmustineCombined Modality TherapyCytarabineDisease-Free SurvivalEtoposideFemaleHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansL-Lactate DehydrogenaseMaleMelphalanMiddle AgedPrognosisRecurrenceTransplantation, AutologousConceptsProgression-free survivalHigh-dose BEAM chemotherapyPeripheral blood progenitor cellsAutologous PBPC transplantationTime of transplantationPrimary refractoryHodgkin's diseaseHigh-dose BEAMBEAM chemotherapyPBPC transplantationOverall survivalAutologous peripheral blood progenitor cell transplantationAutologous peripheral blood progenitor cellsPeripheral blood progenitor cell transplantationBlood progenitor cell transplantationSatisfactory progression-free survivalSevere non-hematologic toxicityWorse progression-free survivalPoor progression-free survivalAutologous PBPC infusionNon-hematologic toxicitiesTransplant-related complicationsConsecutive adult patientsElevated lactate dehydrogenaseRelapse/progression